Certainly hope that we won't be seeing sub $1 dollar again, too many near term catalyst yet to be announced that should support the SP. Endometriosis and Gardia Studies are looking extremely optimistic, The ground work Richard and his team are doing for PromarkerD lays the foundation for much quicker commercialisation of any future diagnostic tests. God knows PromarkD has been too long in the making, many lessons were learnt in the process.
I think an excellent buying opportunity may present itself if phase 2 results don't support a Cdx indication. The market will most likely perceive this as negative news and there may be a sell off,  but it doesn't negate the fact the test still performs as originally designed and the commercialisation will still go forward. I will be looking out for this and will be buying as much as possible during that dip.
PIQ Price at posting:
$1.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)